Back to top
more

Meridian Bioscience Inc. (VIVO)

(Delayed Data from NSDQ)

$11.51 USD

11.51
1,168,817

-0.48 (-4.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Meridian Bioscience (VIVO) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

by Zacks Equity Research

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up

by Zacks Equity Research

Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.

Charles River (CRL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.

IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.

Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates

by Zacks Equity Research

Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Increased digital health adoption and growing pharmacy sales are likely to have contributed to CVS Health's (CVS) Q1 performance.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.

Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.

Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.

Thermo Fisher (TMO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

The negative impact of COVID-19 in the form of supply issues and staffing shortages are expected to have deterred growth in a few areas within the Analytical Instruments business of Thermo Fisher (TMO).

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Based on a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Diagnostics and GYN Surgical businesses is likely to have contributed to Hologic's (HOLX) fiscal second-quarter revenues.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust demand for iTero scanners and increasing Invisalign case submissions are expected to have contributed to Align Technology's (ALGN) Q1 performance.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.

Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.